Amendments to the Claims:

This listing of claims replaces all prior versions and listings of claims in the application:

Listing of Claims:

1-22.   (Canceled).

23. (Currently amended) A method for determining whether a test compound is a candidate compound for modulating the drug resistance of an eukaryotic cell, the method comprising:

a) determining the level of expression of a gene encoding a polypeptide comprising the amino acid sequence encoded by [comprising] the nucleotide sequence of SEQ ID NO:1 in an eukaryotic cell in the presence of a test compound;

b) determining the level of expression of the gene in the eukaryotic cell in the absence of the test compound; and

c) identifying the compound as a candidate modulator of drug resistance of the eukaryotic cell if the level of expression of the gene in the eukaryotic cell in the presence of the test compound differs from the level of expression of the gene in the eukaryotic cell in the absence of the test compound.

24. (Previously presented) The method of claim 23, wherein the eukaryotic cell is a drug resistant cell.

25. (Previously presented) The method of claim 23, wherein the drug resistant eukaryotic cell is a cancer cell.

26. (Previously presented) The method of claim 23, wherein the gene is an endogenous gene.

27. (Previously presented) The method of claim 23, wherein the gene is not an endogenous gene.

28. (Canceled).

29. (New)   The method of claim 23, wherein the candidate modulator increases expression of the gene.

30. (New)   The method of claim 23, wherein the candidate modulator decreases expression of the gene.

31. (New)   The method of claim 23, wherein the step of determining the level of expression comprises measuring mRNA expression.

32. (New)   The method of claim 23, wherein the step of determining the level of expression comprises measuring protein expression.

33. (New)   A method for determining whether a test compound is a candidate compound for decreasing the drug resistance of an eukaryotic cell, the method comprising:

a)   determining the level of expression of a gene encoding a polypeptide comprising the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO:1 in an eukaryotic cell in the presence of a test compound;

b)   determining the level of expression of the gene in the eukaryotic cell in the absence of the test compound; and

c)   identifying the compound as a candidate compound for decreasing drug resistance of the eukaryotic cell if the level of expression of the gene in the eukaryotic cell in the presence of the test compound is less than the level of expression of the gene in the eukaryotic cell in the absence of the test compound.

34. (New)   A method for determining whether a test compound is a candidate compound for increasing the drug resistance of an eukaryotic cell, the method comprising:

a)   determining the level of expression of a gene encoding a polypeptide comprising the amino acid sequence encoded by the nucleotide sequence of SEQ ID NO:1 in an eukaryotic cell in the presence of a test compound;

b)   determining the level of expression of the gene in the eukaryotic cell in the absence of the test compound; and

c)   identifying the compound as a candidate compound for increasing drug resistance of the eukaryotic cell if the level of expression of the gene in the eukaryotic cell in the presence of the test compound is more than the level of expression of the gene in the eukaryotic cell in the absence of the test compound.

35. (New)   The method of claim 33, wherein the eukaryotic cell is a drug resistant cell.

36. (New)   The method of claim 33, wherein the drug resistant eukaryotic cell is a cancer cell.

37. (New)   The method of claim 33, wherein the gene is an endogenous gene.

38. (New)   The method of claim 33, wherein the gene is not an endogenous gene.

39. (New)   The method of claim 33, wherein the candidate modulator increases expression of the gene.

40. (New)   The method of claim 33, wherein the candidate modulator decreases expression of the gene.

41. (New)   The method of claim 33, wherein the step of determining the level of expression comprises measuring mRNA expression.

42. (New)   The method of claim 33, wherein the step of determining the level of expression comprises measuring protein expression.

43. (New)   The method of claim 34, wherein the eukaryotic cell is a drug resistant cell.

44. (New)   The method of claim 34, wherein the drug resistant eukaryotic cell is a cancer cell.

45. (New)   The method of claim 34, wherein the gene is an endogenous gene.

46. (New)   The method of claim 34, wherein the gene is not an endogenous gene.

47. (New)   The method of claim 34, wherein the candidate modulator increases expression of the gene.

48. (New)   The method of claim 34, wherein the candidate modulator decreases expression of the gene.

49. (New)   The method of claim 34, wherein the step of determining the level of expression comprises measuring mRNA expression.

50. (New)   The method of claim 34, wherein the step of determining the level of expression comprises measuring protein expression.